Nicole Rusk

The Search for Genomic Biomarkers of Response to Immunotherapy in Ovarian Cancer

Summary Immune checkpoint blockade has been ineffective in ovarian cancer, and there is an ongoing effort to identify biomarkers of therapeutic benefit. Despite promising preclinical data, a substudy of the IMagyn050 trial found that patients with homologous recombination deficient tumors did not have improved progression-free survival with the addition of the PD-L1 inhibitor atezolizumab. See related article by Landen et al., p. 1698

Ovarian cancer mutational processes drive site-specific immune evasion

High-grade serous ovarian cancer is a genomically complex malignancy. Here the authors integrate whole-genome sequencing, single-cell RNA sequencing, digital histopathology and multiplexed immunofluorescence across 160 tumour sites from 42 patients, revealing that mutational processes shape site-specific immune evasion.

Ongoing genome doubling shapes evolvability and immunity in ovarian cancer

Single-cell whole-genome sequencing of 30,260 tumour genomes from 70 samples across 41 patients in the SPECTRUM cohort reveals that ongoing whole-genome doubling drives tumour evolvability and immune evasion in high-grade serous ovarian cancer.

Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA

Emergence of drug resistance is the main cause of therapeutic failure in patients with high-grade serous ovarian cancer (HGSOC)